menu
    • menu

    Company profile for RyCarma Therapeutics

    NEW Drugs in Dev: 3
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    RyCarma Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for cardiovascular and skeletal muscle diseases. The company leverages deep expertise in ryanodine receptor (RyR) biology to develop a novel class of small-molecule therapeutics called Rycals®. Through its advanced research platform and pipeline, RyCarma aims to address serious unmet medical needs by targeting underlyin...
    RyCarma Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for cardiovascular and skeletal muscle diseases. The company leverages deep expertise in ryanodine receptor (RyR) biology to develop a novel class of small-molecule therapeutics called Rycals®. Through its advanced research platform and pipeline, RyCarma aims to address serious unmet medical needs by targeting underlying disease mechanisms and improving patient outcomes globally

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RyCarma TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Ardsley, New York
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://rycarma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Letting go of Armgo: Biotech rebrands as RyCarma Therapeutics
    Letting go of Armgo: Biotech rebrands as RyCarma Therapeutics

    07 Jan 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/letting-go-armgo-biotech-rebrands-rycarma-therapeutics

    FIERCE PHARMA
    07 Jan 2025
    Share Share
    ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210
    ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210

    19 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230719569965/en

    BUSINESSWIRE
    19 Jul 2023
    Share Share
    Armgo bags $35M for phase 2 heart rhythm study
    Armgo bags $35M for phase 2 heart rhythm study

    21 Dec 2021

    // N.P. Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/forbion-arms-biotech-to-stop-sudden-cardiac-death-leading-35m-round-to-fund-phase-2-trial

    N.P. Taylor FIERCEBIOTECH
    21 Dec 2021
    Share Share
    ARMGO raises $35 million to progress clinical studies of lead molecule ARM210
    ARMGO raises $35 million to progress clinical studies of lead molecule ARM210

    20 Dec 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/12/20/2355102/0/en/ARMGO-Pharma-raises-35-million-to-progress-clinical-studies-of-lead-molecule-ARM210-in-cardiac-and-skeletal-muscle-diseases.html

    GLOBENEWSWIRE
    20 Dec 2021
    Share Share
    ARMGO® Pharma Inc. Announces Clinical Trial of ARM210/S48168
    ARMGO® Pharma Inc. Announces Clinical Trial of ARM210/S48168

    17 Dec 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/armgo-pharma-inc-announces-clinical-trial-of-arm210s48168-for-the-treatment-of-ryanodine-receptor-type-1-related-myopathies-300975427.html

    PR NEWSWIRE
    17 Dec 2019
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search